Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of JNJ-77242113 in adolescents and adults with moderate to severe plaque psoriasis
ISRCTN21453767Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2023
- Modality
- Peptides
01
Overview
Phase 3, randomised, double-blind trial of icotrokinra in plaque psoriasis (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: IGA 0/1 with at least 2-grade improvement from baseline at Week 16 and PASI 90 at Week 16. Started Dec 2023; status: active, not recruiting.
02
Drugs
icotrokinra
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ISRCTN21453767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN21453767.